Camrelizumab, initially known as SHR-1210, represents a significant advancement in malignant treatment, functioning as a biologic that blocks the programmed death-1 receptor. This checkpoint protein, expressed https://socialmediainuk.com/story26780455/camrelizumab-shr-1210-a-deep-analysis-into-the-anti-pd-1-treatment